Pfizer

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of March. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Illumina (NASDAQ: ILMN) and VIVUS (NASDAQ: VVUS) grew somewhat between the...

“This is where money goes to die,” has described one sector over the past decade but this year, things are different. That industry is health care and for the first time since 1988, it leads the S&P with a 12 percent gain—the most among the 10 main groups. Specifically, health insurers,...

A recent report in MarketWatch claimed that if Apple (NASDAQ: AAPL) doesn’t change its ideas towards dividends or buybacks, or finds something else to do with its cash, by the end of 2013 it could reach $170 billion. According to Moody’s, “Unless Apple changes its philosophy towards liquidity/...

On Wednesday, Spectrum Pharmaceuticals (NASDAQ: SPPI) dropped 37 percent after releasing its Q1 and full year revenue guidance. The company said it expects sales of its colorectal cancer drug, Fusilev, to total $80 to $90 million in 2013 compared to $204 million in 2012. Seem like a huge drop...

A recent Australian study points toward possible good news in the search for answers regarding Alzheimer’s disease. The Border Mail reports that Australians will be among the first to test new drugs hoped to ward off Alzheimer’s after researchers discovered that the illness takes decades to...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of January. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Onyx Pharmaceuticals (NASDAQ: ONXX) and Vertex...

In this morning's Marketwatch alert on companies that may report earnings surprises for the fourth quarter, just three were expected to offer positive surprises. Goldman Sachs (NYSE: GS) was seen beating the consensus estimate by up to 18 percent. Forest Laboratories (NASDAQ: FRX) could turn in a...

This weekend in Barron's online: eight categories of low-risk income growth opportunities, what the fiscal cliff deal means for investors, and the prospects for Delta Air Lines and the BRIC countries. Cover Story "Income Winners" by Andrew Bary. There are still plenty of ways to earn up to six...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of December. The number of shares sold short in Amgen (NASDAQ: AMGN), Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN) and Illumina (NASDAQ: ILMN) grew somewhat between the...

This weekend in Barron's online: the outlook for European stocks in 2013, the prospects for PNC Financial Services and Central Garden & Pet, uncovering the hidden potential for higher corporate earnings, and a fresh look at Washington, D.C. Cover Story "Europe on Sale" by Jonathan Buck....

The short interest in biotech and emerging pharmaceutical companies was mixed again in the final two weeks of November. Shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Illumina (NASDAQ: ILMN) and Regeneron Pharmaceuticals (NASDAQ: REGN) grew somewhat between the November 15 and...

Bank of America Merrill Lynch offered some defensive stock picks for 2013 in a research report. Two drug makers and an REIT focused on health care facilities made the list. They were Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE) and Ventas (NYSE: VTR). Here is a quick look at how these three picks...

Three of Fortune's top 10 stock picks for 2013 are health care related companies. But they are not in big names in the sector, such as Johnson & Johnson (NYSE: JNJ) or Pfizer (NYSE: PFE). They were Align Technology (NASDAQ: ALGN), Fresenius Medical Care (NYSE: FMS) and Gilead Sciences (NASDAQ:...

This weekend in Barron's online: stock picks for 2013, speculation about who will be the next Treasury chief and the prospects for Men's Wearhouse, Crosstex Energy and big pharma. Cover Story "Our 10 Favorite Stocks for 2013" by Andrew Bary. Barron's takes a look at where to invest in 2013. The...

The short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of October. Shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN) and VIVUS (NASDAQ: VVUS) grew somewhat between...